Meeting
2023 ASCO Annual Meeting
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.
Authors
Minas P. Economides
New York University, New York, NY
Minas P. Economides , Matthew I. Milowsky , Peter H. O'Donnell , Ajjai Shivaram Alva , Marisa Kollmeier , Tracy L Rose , Sean P. Pitroda , Jonathan E. Rosenberg , Tsivia Hochman , Judith D. Goldberg , Gary D. Steinberg , James Wysock , Peter Schiff , Nicholas J. Sanfilippo , Samir Taneja , David R Wise , Arjun Vasant Balar , William C. Huang , Scot Anthony Niglio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT02621151
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4509)
DOI
10.1200/JCO.2023.41.16_suppl.4509
Abstract #
4509
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
First Author: Andrew James Weickhardt
Poster
2020 ASCO Virtual Scientific Program
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
First Author: Arjun Vasant Balar
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho